Tempus AI has announced a strategic collaboration with Daiichi Sankyo to accelerate the clinical development of antibody-drug conjugates (ADCs) in oncology, highlighting the growing role of artificial intelligence in drug discovery and precision medicine.
The partnership will leverage Tempus’ advanced AI capabilities, including its proprietary multimodal foundation model PRISM2, to generate deeper insights into patient data and improve the design of clinical trials. PRISM2 integrates pathology images with clinical data, enabling researchers to derive diagnostic and predictive insights that may not be evident through traditional analysis methods.
By combining Daiichi Sankyo’s clinical and preclinical research data with Tempus’ extensive real-world oncology database, the collaboration aims to enhance biomarker discovery and patient stratification. These efforts are expected to help identify which patients are most likely to benefit from specific therapies, ultimately improving treatment outcomes and increasing the success rates of clinical trials.
A key focus of the partnership is the development of proof-of-concept AI models designed to optimize patient selection for a novel ADC program. ADCs are a class of targeted cancer therapies that deliver cytotoxic drugs directly to tumor cells via antibodies, minimizing damage to healthy tissues. While highly promising, their clinical success often depends on selecting the right patient populations—an area where AI-driven insights could provide a significant advantage.
The collaboration will also involve deploying these AI models across Tempus’ large-scale oncology dataset to generate detailed “response maps.” These maps will provide a clearer understanding of how different patient subgroups respond to treatment, supporting more precise patient stratification and enabling better benchmarking of control arms in future clinical trials.
According to Ryan Fukushima, the partnership represents a shift in how AI is being applied in drug development. He noted that multimodal AI models are no longer just tools for improving efficiency but are now central to designing more targeted and impactful clinical studies. By uncovering unmet patient needs and identifying those most likely to benefit from new therapies, AI has the potential to significantly reshape oncology research.
For Daiichi Sankyo, the collaboration aligns with its broader strategy to expand its oncology pipeline, particularly in ADCs, an area where the company has already demonstrated strong capabilities. Integrating AI into its development processes could further strengthen its position in this competitive field.
Overall, the partnership underscores the increasing convergence of artificial intelligence, real-world data, and clinical research. As pharmaceutical companies continue to adopt advanced analytics, collaborations like this one may play a crucial role in accelerating innovation and delivering more personalized cancer treatments to patients worldwide.